Clinical Trial

The Swedish BioFINDER - Preclinical AD Study

Recruiting

Summary

This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2023-11-02; most recent amendment 2026-04-01.

Trial Details

NCT Number	NCT06121544
Lead Sponsor	Skane University Hospital Collaborators: Lund University
Conditions	Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Enrollment	800 participants
Start Date	2022-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-06